New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
09:16 EDTPGNX, ABT, EBAY, KOG, URS, ABBV, MYL, AAPL, KNDI, WLL, EXEL, SHPG, RVBD, C, HLIT, ACMOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
News For C;AAPL;EBAY;RVBD;MYL;ABT;SHPG;ABBV;PGNX;EXEL;URS;ACM;WLL;KOG;HLIT;KNDI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 >>
January 28, 2016
09:26 EDTABTAbbott sees global diagnostics sales up mid single digits for Q1, FY16
Subscribe for More Information
09:19 EDTABT, EBAY, EXELOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Facebook (FB), up 13.9%... Under Armour (UA), up 14.6%... MicroStrategy (MSTR), up 8.9%... Harley-Davidson (HOG), up 8%... Paypal (PYPL), up 6%... Mellanox (MLNX), up 7.9%... Cirrus Logic (CRUS), up 6.2%... Alibaba (BABA), up 4.5%. ALSO HIGHER: Neos Therapeutics (NEOS), up 61.4% after the FDA approved Adzenys XR-ODT for the treatment of ADHD... Exelixis (EXEL), up 4.7% after the U.S. FDA determined the company's New Drug Application for cabozantinib is sufficiently complete... Kinder Morgan (KMI), up 6.7% after being upgraded at Credit Suisse and Stifel. DOWN AFTER EARNINGS: OSI Systems (OSIS), down 21.3%... ServiceNow (NOW), down 22.3%... eBay (EBAY), down 11.5%... InvenSense (INVN), down 10.5%... Juniper Networks (JNPR), down 9.3%... Hologic (HOLX), down 4.4%... Abbott Laboratories (ABT), down 3.6%... Potash (POT), down 2.1%... Qualcomm (QCOM), down 3.6%.
09:19 EDTABTAbbott expects EPS to progressively accelerate throughout 2016
Subscribe for More Information
09:04 EDTWLLWhiting Petroleum downgraded to Hold from Buy at Wunderlich
Subscribe for More Information
08:33 EDTEBAYOptions expected to be active
Subscribe for More Information
08:03 EDTEXELExelixis: FDA deems NDA for cabozantinib as 'sufficiently complete'
Exelixis announced that the U.S. FDA has determined the company's New Drug Application for cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received one prior therapy to be sufficiently complete to permit a substantive review. The NDA will be considered officially filed 60 days from the date of the completion of the submission, or February 20, 2016. The FDA granted Priority Review to the filing and assigned a Prescription Drug User Fee Act action date of June 22, 2016. "With FDA granting Priority Review to our application, Exelixis is one step closer to offering physicians cabozantinib as an important new therapeutic option for their patients with advanced renal cell carcinoma," said Michael M. Morrissey, Ph.D., president and CEO of Exelixis. "While we work closely with the FDA during the review process, Exelixis will continue to execute on our commercial plans, including our commitment to be ready for a potential launch by April 1st of this year." A Priority Review designation is granted by the FDA for drugs that, if approved, would be significant improvements in the treatment, prevention or diagnosis of a disease. Previously, the FDA granted cabozantinib Breakthrough Therapy designation and Fast Track designation for the compound's proposed RCC indication. The NDA is based on the results of METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with advanced RCC who experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor. In July 2015, Exelixis announced top-line results demonstrating that the trial had met its primary endpoint of improving progression-free survival; compared with everolimus, cabozantinib was associated with a 42% reduction in the rate of disease progression or death. These data were later presented at the European Cancer Congress in September 2015 and concurrently published in The New England Journal of Medicine.
07:57 EDTEBAYeBay outlook better than headlines suggest, says Baird
Baird said eBay's results were in line with expectations and said although management's outlook looks weak on the surface, the guidance is unchanged from the outlook provided last year. Baird believes eBay shares are likely to be challenged near-term due to foreign exchange headwinds and so lowered its price target to $30 from $33. Baird maintained its Outperform rating on eBay shares.
07:46 EDTAAPLNew iPad Air production to start in Q2, Digitimes reports
Apple is anticipated to unveil its new edition of the iPad Air in March 2016 and production will begin in Q2, with General Interface Solution and TPK to supply touch panels, Digitimes reports, citing Taiwan-based supply chain makers. The new iPad will reportedly come with a 4K resolution panel and up to 4GB in RAM, as well as better battery life, the report says. Reference Link
07:35 EDTABTAbbott sees Q1 EPS ex-items 38c-40c, consensus 47c
Subscribe for More Information
07:34 EDTABTAbbott sees FY16 EPS ex-items $2.10-$2.20, consensus $2.26
Subscribe for More Information
07:33 EDTEBAYeBay share selloff 'feels overdone,' says JPMorgan
Subscribe for More Information
07:33 EDTABTAbbott reports Q4 adjusted EPS 62c, consensus 61c
Subscribe for More Information
07:15 EDTAAPLMarathon Patent Group announces trial date of May 2 in case against Apple
Subscribe for More Information
07:12 EDTABBVAbbVie intiates enrollment in Phase 3 clinical program for Elagolix
AbbVie (ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo. These studies are designed to assess the change in menstrual blood loss utilizing the alkaline hematin method, comparing baseline to month six of treatment. Additional secondary efficacy endpoints are being evaluated; including assessing changes in fibroid volume, monthly blood loss and hemoglobin levels. Bone mineral density will also be assessed.
06:46 EDTAAPLApple may unveil iPad Air 3 at March event, 9to5Mac reports
Subscribe for More Information
06:22 EDTAAPLGoogle, Apple push back on Euro tax deals, FT reports
Subscribe for More Information
06:11 EDTAAPLApple could ship 20M Macs this year, DigiTimes reports
Subscribe for More Information
05:55 EDTEBAYeBay price target lowered to $25 from $30 at Piper Jaffray
Subscribe for More Information
05:54 EDTABBVStocks with implied volatility movement; EMR ABBV
Stocks with implied volatility movement; Emerson (EMR) 38, AbbVie (ABBV) 42 according to iVolatility.
05:37 EDTABBVAbbVie announces venetoclax granted Breakthrough Therapy Designation by FDA
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use